Clinical Research Directory
Browse clinical research sites, groups, and studies.
Circulating Tumor DNA in Melanoma Patients
Sponsor: Institute of Oncology Ljubljana
Summary
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study evaluates the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.
Official title: Significance of Detection and Quantification of Circulating Tumor DNA in the Treatment of Melanoma Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
176
Start Date
2021-11-01
Completion Date
2026-11-30
Last Updated
2026-05-27
Healthy Volunteers
No
Conditions
Interventions
Blood Sampling for ctDNA Analysis
Peripheral blood samples are collected for detection and quantification of circulating tumor DNA (ctDNA). ctDNA results are evaluated in relation to clinical and histopathological prognostic parameters and to recurrence or progression of melanoma during follow-up.
Locations (1)
Institute of Oncology Ljubljana
Ljubljana, Slovenia